Blog
ACE-031: why safety findings matter alongside muscle measurements
An attractive mechanism and a larger muscle measurement are insufficient on their own. A useful summary must include why the study stopped.
Evidence discussed: Randomized human trial.
What the researchers studied
ACE-031 is a receptor fusion protein designed to bind myostatin and related signals. A placebo-controlled trial in boys with Duchenne muscular dystrophy assessed safety and explored muscle, bone and walking outcomes. Several measurements showed trends, but the walking comparison was not statistically significant. [1]
How to interpret the result
The trial stopped after its second dosing regimen because of concerns including nosebleeds and dilated small blood vessels. Trends in lean mass are not proven improvements in strength. This population also differs from healthy athletes.
What readers can take from it
An attractive mechanism and a larger muscle measurement are insufficient on their own. A useful summary must include why the study stopped.
This original editorial summary provides no diagnosis, dosing or treatment advice. The study did not test or certify a PeptiKing product.
Source
[1] Campbell et al., ACE-031 trial in Duchenne muscular dystrophy (2017). PMID: 27462804. Based on the PubMed-indexed abstract and record; full-text methods were not independently reviewed.